Three men face felony charges following a viral New Year's shooting from a Dallas overpass, with investigators linking suspects to a separate road-rage attack and uncovering a cache of firearms.
A mail carrier in Lauderhill faces three counts of animal cruelty following the release of surveillance footage allegedly showing him spraying a resident's three small dogs with a chemical irritant during his delivery route.
A rescue operation in Putnam County, Illinois, ended with one fatality and a second worker airlifted to hospital after both became buried in soybeans while working inside a grain storage bin.
Charles Broomfield, who once wore a '#1 Dad' lanyard, now faces murder charges after allegedly confessing to shooting his fiancée and her two teenage sons in their Grand Rapids home, while his own young child was spared.
Brendan Banfield's murder trial reaches its climax Friday with closing arguments after he testified he shot a man he found stabbing his wife. Prosecutors allege an elaborate murder-for-hire plot, while the defense claims a tragic act of self-defense.
In a new court filing, Hunter Biden's legal team moves to dismiss a contempt motion brought by the mother of his 7-year-old daughter, arguing his relationship with the child is legally irrelevant and denying violations of their 2023 support agreement.
The abduction of nearly 200 residents from Kurmin Wali has shattered community life, triggering a wave of departures as survivors lose faith in state protection and face an uncertain future.
The resignation of Prudential Financial's Japan life insurance CEO following a widespread employee misconduct scandal has triggered governance reviews and shaken investor confidence in one of the insurer's key international markets.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Champion Iron reports steady Q3 operational performance with improved costs and significant progress on its high-grade DRPF project. The company also details the fully-financed plan to acquire Norway's Rana Gruber, aiming to strengthen its foothold in the European steelmaking market.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
As the STOXX Europe 600 grapples with volatility, some investors are turning their gaze to smaller, often overlooked companies. We examine three European penny stocks, each with a market capitalization exceeding €10 million, assessing their potential amidst a challenging macroeconomic backdrop.
Despite a challenging price environment, Murphy Oil (MUR) reported strong operational execution for 2025 and laid out a capital plan focused on funding key international and offshore projects. While near-term production is set to dip, CEO Eric Hambly highlighted a transformative discovery in Vietnam and strategic portfolio expansion as pillars for future growth.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Dolby Laboratories (DLB) reported first-quarter results that exceeded analyst forecasts, prompting the company to raise its full-year guidance. The audio-visual technology leader cited earlier-than-anticipated deal closures, momentum in mobile and broadcast, and strategic wins with partners like Sony, TCL, and Peacock as key drivers.
An international tribunal has ruled against Shell and partner Eni in a cost-recovery dispute at Kazakhstan's Karachaganak field, potentially exposing the energy giants to a multi-billion dollar payout and forcing contract renegotiations that could reshape future cash flows from the strategic asset.
